Brussels sector inquiry report due on November 28th
This article was originally published in Scrip
A preliminary report on theEuropean Commission's sector inquiry into competition in pharmaceuticals is to be presented on November 28th. The commission says the findings will, as necessary, allow competition authorities at European or national level to focus on the most serious competition concerns and identify remedies to resolve specific problems in individual cases.
You may also be interested in...
Local health authorities in Coventry, UK, say it is most unlikely that vaccination with GlaxoSmithKline's Cervarix (human papillomavirus vaccine) was the cause of the death of a 14-year-old schoolgirl on September 28th.
Patents on Janssen-Cilag's (Johnson & Johnson) anti-epileptic Topamax/Epitomax (topiramate) expired in many European countries on September 25th, and generics companies are launching their own versions quickly.
Lilly's Alimta (pemetrexed) has been recommended as a first-line treatment for some patients in England and Wales with non-small cell lung cancer (NSCLC) in binding guidance for the national health service.